Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.
Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B, Caldera V, Nava S, Ravanini M, Facchetti F, Bruzzone MG, Finocchiaro G. Pellegatta S, et al. Among authors: bruzzone mg. Cancer Res. 2006 Nov 1;66(21):10247-52. doi: 10.1158/0008-5472.CAN-06-2048. Cancer Res. 2006. PMID: 17079441 Free article.
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L, Pollo B, Bissola L, Silvani A, Bianchessi D, D'Incerti L, Filippini G, Broggi G, Boiardi A, Finocchiaro G. Eoli M, et al. Among authors: bruzzone mg. Clin Cancer Res. 2007 May 1;13(9):2606-13. doi: 10.1158/1078-0432.CCR-06-2184. Clin Cancer Res. 2007. PMID: 17473190
The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates.
Pellegatta S, Eoli M, Frigerio S, Antozzi C, Bruzzone MG, Cantini G, Nava S, Anghileri E, Cuppini L, Cuccarini V, Ciusani E, Dossena M, Pollo B, Mantegazza R, Parati EA, Finocchiaro G. Pellegatta S, et al. Among authors: bruzzone mg. Oncoimmunology. 2013 Mar 1;2(3):e23401. doi: 10.4161/onci.23401. Oncoimmunology. 2013. PMID: 23802079 Free PMC article.
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Porrati P, Di Stefano AL, Ceroni M, Bertolini F, Finocchiaro G, Eoli M. Cuppini L, et al. Among authors: bruzzone mg. PLoS One. 2013 Sep 12;8(9):e74345. doi: 10.1371/journal.pone.0074345. eCollection 2013. PLoS One. 2013. PMID: 24069296 Free PMC article.
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.
Nava F, Tramacere I, Fittipaldo A, Bruzzone MG, Dimeco F, Fariselli L, Finocchiaro G, Pollo B, Salmaggi A, Silvani A, Farinotti M, Filippini G. Nava F, et al. Among authors: bruzzone mg. Neuro Oncol. 2014 May;16(5):719-27. doi: 10.1093/neuonc/not316. Epub 2014 Jan 23. Neuro Oncol. 2014. PMID: 24463354 Free PMC article.
168 results